AstraZeneca Investment China

AstraZeneca is a global leading multinational pharmaceutical enterprise with a global turnover of over 29.6 billion US dollars in 2007. AstraZeneca's headquarters is located in London, UK, and it has 67,000 employees worldwide. Its business scope covers more than 100 countries and regions globally. AstraZeneca has 29 production bases in 20 countries around the world. AstraZeneca possesses strong research and development capabilities, with a total R&D investment of 5 billion US dollars in 2007. It has 17 R&D institutions in 8 countries (US, UK, France, Sweden, Canada, Japan, China, India), where approximately 13,000 employees are engaged in work related to new drug development. AstraZeneca provides innovative and highly effective pharmaceutical products to patients in six major therapeutic areas, including gastroenterology, cardiovascular, oncology, central nervous system, respiratory, and anti-infectives, many of which hold leading positions in the world. In 2006, AstraZeneca began entering the antibiotics field, developing a new generation of antibiotics for treating critically ill patients with severe infections that are highly resistant to existing antibiotics.